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Abstract
Background: The treatment of migraine is impeded by several difficulties, among which insufficient headache
relief, side effects, and risk for developing medication overuse headache (MOH). Thus, new acutely acting
antimigraine drugs are currently being developed, among which the small molecule CGRP receptor antagonists,
gepants, and the 5-HT1F receptor agonist lasmiditan. Whether treatment with these drugs carries the same risk for
developing MOH is currently unknown.
Main body: Pathophysiological studies on MOH in animal models have suggested that decreased 5-
hydroxytryptamine (5-HT, serotonin) levels, increased calcitonin-gene related peptide (CGRP) expression and
changes in 5-HT receptor expression (lower 5-HT1B/D and higher 5-HT2A expression) may be involved in MOH. The
decreased 5-HT may increase cortical spreading depression frequency and induce central sensitization in the
cerebral cortex and caudal nucleus of the trigeminal tract. Additionally, low concentrations of 5-HT, a feature often
observed in MOH patients, could increase CGRP expression. This provides a possible link between the pathways of
5-HT and CGRP, targets of lasmiditan and gepants, respectively. Since lasmiditan is a 5-HT1F receptor agonist and
gepants are CGRP receptor antagonists, they could have different risks for developing MOH because of the different
(over) compensation mechanisms following prolonged agonist versus antagonist treatment.
Conclusion: The acute treatment of migraine will certainly improve with the advent of two novel classes of drugs,
i.e., the 5-HT1F receptor agonists (lasmiditan) and the small molecule CGRP receptor antagonists (gepants). Data on
the effects of 5-HT1F receptor agonism in relation to MOH, as well as the effects of chronic CGRP receptor blockade,
are awaited with interest.
Keywords: Migraine, Medication overuse headache, Chronic migraine, Acute antimigraine drugs, Triptans, Gepants,
Ditans, Lasmiditan
Background
The neurovascular disorder migraine is one of the most
common diseases worldwide [1, 2]. While the group of
headache disorders is one of the top three causes of
years lost to disease (YLDs), migraine is responsible for
approximately 87% of these YLDs [3]. Migraine treat-
ment can be divided into acutely acting and preventive
treatment. The acutely acting treatment can be further
subdivided into migraine-specific treatment and analge-
sics, which are non-specific drugs [4]. Unfortunately, the
current acutely acting treatments do not provide ad-
equate relief of migraine symptoms for all patients [4–6]
and, when used frequently, can cause the disease to de-
velop into medication overuse headache (MOH) [7–9], a
debilitating disorder estimated to be responsible for ap-
proximately 2% of all YLDs [10]. MOH is defined as
headache for ≥15 days per month in a patient with
pre-existing primary headache, while taking acutely act-
ing medication for 3 months and ≥ 10 or ≥ 15 days per
month, in case of specific anti-migraine drugs or simple
analgesics, respectively [3, 7].
This unmet need for adequate and safe treatment of mi-
graine has resulted in the development of new drugs,
among which 5-HT1F receptor agonists such as
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lasmiditan, and small molecule CGRP receptor antago-
nists (gepants) [11–13]. Even though uncertainties regard-
ing long-term effects and precise mechanism of action
remain [14–17] and the development of some gepants
[18–20] was terminated because of pharmacokinetic or
safety concerns, the gepants that are still in development
and lasmiditan show promising results in terms of efficacy
and side-effects [4, 5, 21]. However, their relationship with
medication overuse headache has obviously not yet been
described because of the novelty of these drugs. For ex-
ample, the mean duration until onset of MOH for trip-
tans, ergots, and analgesics is 1.7 years, 2.7 years, and 4.8
years, respectively [22]. This makes it impossible to draw
conclusions based upon clinical trials regarding the
long-term use of gepants and lasmiditan, and MOH, not
knowing what the duration until onset, if there is any
MOH, might be for these new drugs.
From epidemiological, clinical, and fundamental ani-
mal studies, a substantial amount of evidence regarding
the pathophysiology of MOH is available [8, 22–26], we
will in this review combine this with the current know-
ledge about the characteristics of CGRP, gepants, and
lasmiditan [12, 27–32] in an attempt to generate a rele-
vant hypothesis regarding MOH and these novel acutely
acting antimigraine drugs. To achieve this, we will first
shortly review the drugs currently used in the treatment
of migraine, after which MOH and its pathophysiology
will be discussed, to conclude with new acutely acting
drugs in development, and how these drugs are expected
to relate to MOH.
Current acutely acting antimigraine drugs
The most commonly used approaches for the acute
treatment of migraine have been extensively reviewed
from several perspectives [4, 13, 33–35]. These ap-
proaches include the administration of ergot alkaloids
(ergots), triptans, NSAIDs, and paracetamol. NSAIDs
and paracetamol are both effective in the treatment of
migraine, but are considered to be non-specific antimi-
graine drugs, as they are general analgesics [36–38]. The
oldest migraine-specific drugs are the ergots, dating back
to before 1900 [39, 40]. Even though several ergots have
been shown to be effective against migraine, dihydroer-
gotamine (DHE) is the best tolerated of this class. How-
ever, DHE still has more adverse effects than the current
drugs. Thus, in practice, 5-HT1B/1D agonists (triptans
[41]) are most commonly used. However, a significant
proportion of migraine patients experiences insufficient
relieve of their attacks, and triptans and ergots are con-
traindicated in patients with increased cardiovascular
risk [42–44]. Additionally, frequent use of any acutely
acting antimigraine drugs carries a risk for developing
MOH. This results in inadequate treatment of the mi-
graine population as a whole.
Medication overuse headache
As described above, MOH is a disorder with headache
for ≥15 days per month in a patient with pre-existing
headache, while taking acutely acting medication for ≥3
months according to certain requirements [3]. From a
clinical perspective, MOH is present in about 1% of the
general population, and develops mainly in patients with
pre-existing migraine (ca. 70% of all MOH cases), or
tension-type headache [24, 45] with chronic migraine
(CM) being a form of migraine with especially high
prevalence of MOH [45]. All classes of acutely acting
antimigraine drugs are able to cause development of
MOH [22, 23], although clinical differences, such as dif-
ferent mean duration until onset of MOH, remain [22].
MOH patients exhibit, in general, several behavioral
characteristics that are also seen in substance abuse or
drug addiction [46, 47]. This seems to be in accordance
with observations regarding the relapse rate after suc-
cessful treatment. Although this rate is variable across
studies from various countries investigating different
separate populations (e.g. populations with triptan over-
use, opioid overuse, and / or comorbid psychiatric disor-
ders), the majority shows a relapse rate of 25–35% [45,
48]. Research on the pathophysiology of MOH has, until
now, developed in mainly two directions. The first being
epidemiological and clinical research on MOH patients,
the second pertaining to animal models of MOH. Ani-
mal models of CM and MOH usually (repeatedly) ad-
minister acutely acting antimigraine drugs (e.g.
sumatriptan, paracetamol, opioids) to induce MOH [9,
25, 49–51], or apply nitroglycerin (NO donor) [52–54]
or an inflammatory soup on the dura mater [55, 56] to
induce CM (with features similar to MOH). These
models exhibit several phenotypes that relate to CM as
well as MOH, such as mechanical hyperalgesia, photo-
phobia, nociceptive behavior, and facial grooming. How-
ever, these models are obviously an imperfect
representation of the clinical characteristics. For ex-
ample, a major critique is that these models cause simi-
lar phenotypes, but through a completely different
mechanism. Although this may be a strong point, it
seems to fit with observations in the clinical situation
where diverse classes of drugs may cause similar features
of MOH. An obvious difference is that MOH only de-
velops in patients with pre-existing headaches, while in
the MOH models naïve mice are exposed to the
MOH-inducing drugs. Similarities with the clinical dis-
orders and shortcomings of the animal models are ex-
tensively reviewed elsewhere [57]. Utilizing an animal
model for MOH, it was shown in 2010 that triptans can
induce central sensitization in rats, which could possibly
function as a basis for MOH [9]. Since then, ample stud-
ies have confirmed that chronical application of drugs
like paracetamol [51] and opiates [29, 58, 59] have
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similar effects, which could possibly underlie the patho-
genesis of MOH. Two common observations in MOH
models are that CGRP expression increases [9, 25, 28,
30] and 5-HT1B/D receptor expression decreases [60, 61]
upon prolonged exposure to antimigraine drugs in ani-
mal models. Clinical research has shown that 5-HT
levels are decreased in patients with MOH [8, 26, 62].
This decrease in 5-HT levels might subsequently upreg-
ulate the pronociceptive 5-HT2A expression [63]. Such
an upregulation of 5-HT2A expression is also observed
in animal models of MOH [51]. Additionally, reduced
5-HT concentrations in animal models resulted in in-
creased amount of CSDs and hyperexcitability in the
cortex and the nucleus caudalis of the trigeminal tract
[64–66], mimicking clinical observations in patients with
migraine and decreased 5-HT levels. Furthermore, these
lower 5-HT levels may also increase CGRP expression
[45, 63], providing a possible connection between the in-
creased CGRP and decreased 5-HT levels observed in
MOH patients. Blocking CGRP receptors with a mono-
clonal antibody (mAb) has shown to reduce the risk for
cutaneous allodynia, which was used as a proxy for
MOH in an animal model utilizing nitroglycerin as in-
ducer [27]. This is in accordance with the concept that
increased CGRP levels may be involved in the pathogen-
esis of MOH [67], although it should be kept in mind
that other recent studies did not confirm that systemic
CGRP levels are increased in medication overuse head-
ache [68, 69]. In conclusion, decreased 5-HT, increased
5-HT2A receptor level and possibly increased CGRP ex-
pression seem to be involved in the pathophysiology of
MOH, based upon animal research models.
Prospective acutely acting antimigraine drugs
The development of new acutely acting drugs has mainly
been driven by growing understanding of the pathophysi-
ology of migraine, together with the above-mentioned
shortcomings of the currently available drugs. For ex-
ample, small-molecule CGRP receptor antagonists
(gepants) [70], specific 5-HT1F receptor agonists [21],
TRPV1 receptor antagonists [71–73], EP4 receptor (with
PGE2 as ligand) antagonists [74], and glutamate receptor
antagonists [13] have all been pursued because of their
link to migraine pathophysiology [75]. Some of these were,
unfortunately, discontinued because of non-superiority
over placebo in clinical trials [4]. Currently, the most
promising and clinically advanced candidate drugs are las-
miditan (5-HT1F receptor agonist) [12, 21, 76, 77] and
gepants (CGRP receptor antagonists) [31, 70, 78, 79]. Las-
miditan is a specific 5-HT1F receptor agonist, whereas
triptans have a higher affinity for the 5-HT1B/1D receptors
[12]. This difference in affinity is important because trip-
tans are thought to contract the middle meningeal arteries
[80], coronary arteries [43, 81], and increase the blood
pressure [82] through their action on the 5-HT1B receptor
[42], for which lasmiditan has no affinity at clinically rele-
vant concentrations. Consequently, where sumatriptan
has been shown to have the potential to constrict coronary
and carotid arteries in vivo [44] and in vitro [83], lasmidi-
tan did not possess any vasoconstrictor properties in these
studies. Because coronary artery constriction brings a car-
diovascular risk and lasmiditan does not constrict the cor-
onary arteries either in vitro or in vivo, lasmiditan does
not appear to carry the same cardiovascular risk as trip-
tans, which makes it potentially applicable to a wider
population. Although it has a lower risk for cardiovascular
side effects, lasmiditan may induce central side effects
such as dizziness, fatigue, and paresthesia [12, 76]. Simul-
taneously with the research focusing on the 5-HT1F recep-
tor agonist lasmiditan, multiple gepants (small molecule
CGRP receptor antagonists) are currently being developed
for the treatment of migraine [70, 84]. The gepants still in
development for the acute treatment of migraine, ubroge-
pant and rimegepant, show a significant effect compared
to placebo, although their efficacy relative to other antimi-
graine treatments remains to be explored [85]. They seem
to cause less side effects than existing anti-migraine drugs,
but could potentially carry a cardiovascular risk [16] as
CGRP is known to possess cardioprotective properties
[86]. Additionally, CGRP/calcitonin knock-out animal
models have demonstrated to be more susceptible for
hypertension when hypertension is triggered [87, 88].
Presently there is not sufficient evidence to determine
whether gepants will have side effects on the cardiovascu-
lar system. In summary, the two most promising new
acutely acting antimigraine drugs are lasmiditan and the
gepants, where lasmiditan has a low cardiovascular risk
but central side effects and gepants show the least side ef-
fects but potentially could carry a cardiovascular risk, al-
though not sufficient evidence to support or refute this
concern is available at the moment.
Pharmacology of lasmiditan, CGRP and MOH
A question that is of great interest, is whether novel drugs
like lasmiditan and the gepants will have the capability to
induce MOH. While, as outlined above, the exact mecha-
nisms behind MOH are currently unknown, it makes
sense to hypothesize that MOH may have to do with
desensitization and / or downregulation of the receptors
involved in the drug response. It is likely that treatment
with agonists will lead to a receptor desensitization and /
or downregulation, while treatment with receptor antago-
nists will lead to receptor upregulation [89] (Fig. 1), as
previously reported in depth for the ß-adrenoceptor ago-
nists used for cardiovascular indications [90]. Besides dir-
ect effects on the receptors involved, different classes of
drugs leading to MOH may also affect up- or downregula-
tion of the targeted receptor / pathways, potentially
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leading to a common downstream mechanism inducing
MOH. Admittedly, many aspects, such as differential
intracellular signaling pathways [91] are still incompletely
understood. In addition, migraine patients may have a
specific (epi) genetic propensity leading to MOH, which
may not be reflected in animal models. While triptans are
known to have the propensity of inducing MOH when
taken too frequently, it is not known whether selective
5-HT1F receptor agonists, such as lasmiditan, carry the
same risk. Theoretically, this could be possible because
the 5-HT1B, 5-HT1D and 5-HT1F receptors all bind to a
Gi/o–coupled receptor and negatively couple to adenylyl
cyclase and, thus, share the same effect: decreased produc-
tion of cyclic AMP [92, 93]. On the other hand, stimula-
tion of the 5-HT1F (as well as 5-HT1D) receptor, which
has been described to be present in blood vessels [94],
does not constrict these blood vessels, despite the shared
second messenger pathway with the 5-HT1B receptor,
underlining that not all characteristics of stimulation of
certain receptors can be predicted based on their shared
intracellular signaling pathways. Clearly, 5-HT1B/1D recep-
tor agonists with a poor potency at the 5-HT1F receptor,
such as ergotamine, are also capable of inducing MOH
[95], so the 5-HT1F receptor is not required for this
phenomenon. There are, to the best of our knowledge,
currently no data suggesting that the 5-HT1F receptor
would or would not be involved in the generation of
MOH, so clinical data on the frequent use of 5-HT1F re-
ceptor agonists such as lasmiditan are awaited with
interest.
Regarding CGRP receptor blockade, chronic and fre-
quent administration of gepants has been attempted in
clinical trials investigating prophylactic treatment of mi-
graine [19, 84, 96, 97], and chronic blockade of the
CGRP receptor is also achieved by administration of the
monoclonal antibody erenumab. Currently, there are no
data suggesting that chronic blockade of the CGRP re-
ceptor will induce MOH, although long-term effects of
administration of CGRP (receptor) – blocking drugs on
CGRP receptor signaling should definitely be studied
[98]. While blocking CGRP (receptors) is an effective ap-
proach for treating migraine, chronic use could in theory
result in an increase of CGRP (receptor) expression.
However, it is currently unknown whether expression of
Fig. 1 Schematic representation of potential receptor expression changes upon chronic drug use. Receptor expression in the cell membrane in
healthy condition (a), after prolonged agonist exposure (b), and after prolonged antagonist exposure (c). After prolonged agonist exposure,
downregulation and desensitization (by arrestin binding after phosphorylation by GPCR Kinase) could occur. After prolonged antagonist exposure,
receptor upregulation is expected to take place
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CGRP (receptors) will increase or decrease under these
circumstances [98]. Furthermore, the hypothesis that
CGRP has an indirect and direct positive feedback loop
was proposed by Russo in 2015 [15]. This would, in the-
ory, imply that (chronically) blocking CGRP would not
be answered with an (over) compensation or upregula-
tion of CGRP receptors. For 5-HT, on the contrary, ap-
plying triptans results in a decrease in 5-HT levels. In
summary, it will be fascinating to study the conse-
quences of, and potential differences between, the
chronic administration of 5-HT receptor agonists and
CGRP receptor antagonists.
CGRP and medication overuse headache
As described above, CGRP is a central component of mi-
graine. Levels of CGRP are increased in animal models
of MOH, which is probably reflecting CGRP levels in
MOH patients [67–69], and blocking CGRP with an
antibody prevents the development of a proxy for MOH
in a rodent model [27]. Not only does blocking CGRP
(receptors) seem to prevent MOH formation, but also
has it been shown to reduce headache in clinical trials of
MOH treatment [99–101]. In summary, 1) currently no
conclusion can be drawn as to whether CGRP, or CGRP
receptor, expression will increase upon blockade of ei-
ther of the two; 2) blocking the CGRP pathway prevents
formation of a proxy of MOH in a rodent model [27];
and 3) reduces headache in clinical trials of MOH treat-
ment [99–101]. Thus, the CGRP pathway seems to be a
possible candidate in the safe acute (and preventive)
treatment of migraine, maintaining a low risk for MOH
development. Possibly, it could even contribute to symp-
tom alleviation in already clinically established MOH.
However, the effects of long-term blockade of CGRP or
its receptors remain to be investigated properly.
Other novel acutely acting antimigraine drugs and
medication overuse headache
Opposed to current acutely acting antimigraine drugs
and drugs acting on the CGRP pathway, the relationship
with MOH has not extensively been discussed or investi-
gated for novel acutely acting antimigraine drugs. For
example, although lasmiditan has been extensively inves-
tigated with regard to risk for cardiovascular side effects
and efficacy of migraine treatment as described above,
currently no data are available regarding its relation to
MOH [102]. To estimate the risk for MOH development
in patients using lasmiditan, several aspects of the drug
should be considered, as mentioned above in this review.
We look forward to novel studies shedding more light
on these characteristics of the prospective antimigraine
drugs.
Conclusion
In conclusion, the acute treatment of migraine will cer-
tainly improve with the advent of two novel classes of
drugs, i.e., the 5-HT1F receptor agonists and the small
molecule CGRP receptor antagonists (gepants). Data on
the effects of 5-HT1F receptor agonism in relation to
MOH, as well as the effects of chronic CGRP receptor
blockade, are awaited with interest.
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